Servier Renews and Expands License to Aureus
News Mar 02, 2006
Aureus Pharma has announced that Servier has both renewed their previous license to Aureus’ AurSCOPE ADME/Drug-Drug Interactions (ADME/DDI) knowledge database and expanded the license to include AurSCOPE GPCR as well.
Servier became Aureus’ first customer of the AurSCOPE ADME/DDI knowledgebase in 2002. During the subsequent years, Aureus and Servier have collaborated closely to develop and enhance the AurSCOPE ADME/DDI.
This knowledge database contains all relevant biological and chemical information related to the metabolic properties of drugs and is designed to assist in the identification of potential drug-drug interactions.
"We have found that Aureus Pharma’s high quality ADME/ Drug-Drug Interaction knowledge databases are a source of crucial information in identifying potential adverse drug-drug interactions," said Dr. Bernard Marchand, Servier’s Director of Biopharmacy.
"We also look forward to applying the AurSCOPE GPCR knowledgebase in a variety of our disease targeted programs," added Dr. Emmanuel Canet, Vice President Research at Servier.
"We are delighted that Servier has chosen to continue their collaboration with Aureus Pharma," said Dr. Andre Michel, CEO of Aureus Pharma.
"Strong partnership with pharmaceutical companies such as Servier is strategic to Aureus in the ongoing development of solutions fitting with the needs of our end users."
More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?READ MORE
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent painful swellings of the skin and mucous membranes. A new drug has been developed to help prevent attacks of hereditary angioedema. It has now been investigated in an international study performed at over 26 university facilities in Europe, Canada and Australia.READ MORE